Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Introducing the MUC16 gene: implications for prevention and early detection in epithelial ovarian cancer.

McLemore MR, Aouizerat B.

Biol Res Nurs. 2005 Apr;6(4):262-7. Review.

PMID:
15788735
2.

Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone.

White NM, Mathews M, Yousef GM, Prizada A, Fontaine D, Ghatage P, Popadiuk C, Dawson L, Doré JJ.

Cancer Biomark. 2009;5(6):279-87. doi: 10.3233/CBM-2009-0113.

PMID:
20037204
3.

Polymorphisms in the MUC16 gene: potential implication in epithelial ovarian cancer.

Bouanene H, Hadj Kacem H, Ben Fatma L, Ben Limem H, Ben Ahmed S, Yakoub S, Miled A.

Pathol Oncol Res. 2011 Jun;17(2):295-9. doi: 10.1007/s12253-010-9314-2.

PMID:
21046495
4.

New tumor markers: CA125 and beyond.

Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K.

Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. Review.

PMID:
16343244
5.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

6.

Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125).

Chauhan SC, Singh AP, Ruiz F, Johansson SL, Jain M, Smith LM, Moniaux N, Batra SK.

Mod Pathol. 2006 Oct;19(10):1386-94.

7.

Ovarian cancer screening: a look at the evidence.

Fields MM, Chevlen E.

Clin J Oncol Nurs. 2006 Feb;10(1):77-81. Review.

PMID:
16482731
8.

Screening and detection of ovarian cancer.

Breedlove G, Busenhart C.

J Midwifery Womens Health. 2005 Jan-Feb;50(1):51-4. Review.

PMID:
15637515
9.

Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.

Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13.

10.

Current clinical use of biomarkers for epithelial ovarian cancer.

Moore RG, Maclaughlan S.

Curr Opin Oncol. 2010 Sep;22(5):492-7. doi: 10.1097/CCO.0b013e32833c3351. Review.

PMID:
20613519
11.

Systematic evaluation of candidate blood markers for detecting ovarian cancer.

Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW, Brown PO, Nelson BH, Urban N.

PLoS One. 2008 Jul 9;3(7):e2633. doi: 10.1371/journal.pone.0002633.

12.

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.

Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M.

Int J Gynecol Cancer. 2005 Sep-Oct;15(5):679-91.

PMID:
16174214
13.

No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.

Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N, Fink D, Heinzelmann-Schwarz V.

Gynecol Oncol. 2011 Jun 1;121(3):487-91. doi: 10.1016/j.ygyno.2011.02.022.

PMID:
21420727
14.

Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.

Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, Kim NW, McIntosh MW.

Gynecol Oncol. 2007 Jul;106(1):112-8.

PMID:
17490732
15.
16.

MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.

Thériault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, Boivin M, Piché A, Rancourt C.

Gynecol Oncol. 2011 Jun 1;121(3):434-43. doi: 10.1016/j.ygyno.2011.02.020.

PMID:
21421261
17.

Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.

Arits AH, Stoot JE, Botterweck AA, Roumen FJ, Voogd AC.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):621-8.

PMID:
17868339
18.

CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.

Boivin M, Lane D, Piché A, Rancourt C.

Gynecol Oncol. 2009 Dec;115(3):407-13. doi: 10.1016/j.ygyno.2009.08.007.

PMID:
19747716
19.

Biomarker discovery in epithelial ovarian cancer by genomic approaches.

Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ.

Adv Cancer Res. 2007;96:1-22. Review.

PMID:
17161674
20.

[Tumor marker in ovarian cancer].

Komai K, Nishida T.

Gan To Kagaku Ryoho. 2002 Mar;29(3):481-6. Review. Japanese.

PMID:
11915744

Supplemental Content

Support Center